Solomon, Scott D.

Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure

Teerlink, J. R., Diaz, R., Felker, G. M., McMurray, J. J. V., Metra, M., Solomon, S. D., Adams, K. F., Anand, I., Arias-Mendoza, A., Biering-Sørensen, T., et al. (2021) · New England Journal of Medicine

Heart Failure Treatment and ManagementCardiomyopathy and Myosin Studies

Cited by 656

Association of change in N-terminal pro-B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction

Januzzi, J. L., Prescott, M. F., Butler, J., Felker, G. M., Maisel, A. S., McCague, K., Camacho, A., Piña, I. L., Rocha, R. A., Shah, A. M., et al. (2019) · JAMA

Heart Failure Treatment and ManagementCardiac Fibrosis and Remodeling

Cited by 634

Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure

Solomon, S. D., Vaduganathan, M., L. Claggett, B., Packer, M., Zile, M., Swedberg, K., Rouleau, J., A. Pfeffer, M., Desai, A., H. Lund, L., et al. (2020) · Circulation

Heart Failure Treatment and ManagementHeart rate and cardiovascular health

Cited by 551

Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes

Petrie, M. C., Verma, S., Docherty, K. F., Inzucchi, S. E., Anand, I., Belohlávek, J., Böhm, M., Chiang, C.-E., Chopra, V. K., de Boer, R. A., et al. (2020) · JAMA

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 531

Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program

Rådholm, K., Figtree, G., Perkovic, V., Solomon, S. D., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Barrett, T. D., Shaw, W., Desai, M., et al. (2018) · Circulation

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 488

Prognostic Importance of Impaired Systolic Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone

Shah, A. M., Claggett, B., Sweitzer, N. K., Shah, S. J., Anand, I. S., Liu, L., Pitt, B., Pfeffer, M. A., & Solomon, S. D. (2015) · Circulation

Cardiovascular Function and Risk FactorsHeart Failure Treatment and Management

Cited by 478

Erythropoietic response and outcomes in kidney disease and type 2 diabetes

Solomon, S. D., Uno, H., Lewis, E. F., Eckardt, K.-U., Lin, J., Burdmann, E. A., de Zeeuw, D., Ivanovich, P., Levey, A. S., Parfrey, P., et al. (2010) · New England Journal of Medicine

Erythropoietin and Anemia TreatmentBiosimilars and Bioanalytical Methods

Cited by 473

Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis: Analysis of the APOLLO Study

Solomon, S. D., Adams, D., Kristen, A., Grogan, M., González-Duarte, A., Maurer, M. S., Merlini, G., Damy, T., Slama, M. S., Brannagan, T. H., et al. (2019) · Circulation

Amyloidosis: Diagnosis, Treatment, OutcomesAlzheimer's disease research and treatments

Cited by 462

A Trial to Evaluate the Effect of the Sodium–Glucose Co-Transporter 2 Inhibitor Dapagliflozin on Morbidity and Mortality in Patients with Heart Failure and Reduced Left Ventricular Ejection Fraction (DAPA-HF)

McMurray, J. J. V., DeMets, D. L., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Langkilde, A. M., Martinez, F. A., Bengtsson, O., Ponikowski, P., Sabatine, M. S., et al. (2019) · European Journal of Heart Failure

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 433

Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study

Pieske, B., Maggioni, A. P., Lam, C. S. P., Pieske-Kraigher, E., Filippatos, G., Butler, J., Ponikowski, P., Shah, S. J., Solomon, S. D., Scalise, A.-V., et al. (2017) · European Heart Journal

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 366

Risk Related to Pre–Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial

Kristensen, S. L., Preiss, D., Jhund, P. S., Squire, I., Cardoso, J. S., Merkely, B., Martinez, F., Starling, R. C., Desai, A. S., Lefkowitz, M. P., et al. (2016) · Circulation Heart Failure

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 359

Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria

Neuen, B. L., Heerspink, H. J. L., Vart, P., Claggett, B. L., Fletcher, R. A., Arnott, C., de Oliveira Costa, J., Falster, M. O., Pearson, S.-A., Mahaffey, K. W., et al. (2024) · Circulation

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 358

Fewer Hospitalizations for Acute Cardiovascular Conditions During the COVID-19 Pandemic

Bhatt, A. S., Moscone, A., McElrath, E. E., Varshney, A. S., Claggett, B. L., Bhatt, D. L., Januzzi, J. L., Butler, J., Adler, D. S., Solomon, S. D., et al. (2020) · Journal of the American College of Cardiology

COVID-19 and healthcare impactsCOVID-19 Clinical Research Studies

Cited by 357

Heart failure with preserved ejection fraction: from mechanisms to therapies

Lam, C. S. P., Voors, A. A., de Boer, R. A., Solomon, S. D., & van Veldhuisen, D. J. (2018) · European Heart Journal

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 355

Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial

Kosiborod, M. N., Jhund, P. S., Docherty, K. F., Diez, M., Petrie, M. C., Verma, S., Nicolau, J. C., Merkely, B., Kitakaze, M., DeMets, D. L., et al. (2020) · Circulation

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 350

Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF

Jhund, P. S., Solomon, S. D., Docherty, K. F., Heerspink, H. J. L., Anand, I. S., Böhm, M., Chopra, V., de Boer, R. A., Desai, A. S., Ge, J., et al. (2021) · Circulation

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 307

Longitudinal and Circumferential Strain Rate, Left Ventricular Remodeling, and Prognosis After Myocardial Infarction

Hung, C.-L., Verma, A., Uno, H., Shin, S.-H., Bourgoun, M., Hassanein, A. H., McMurray, J. J., Velazquez, E. J., Kober, L., Pfeffer, M. A., et al. (2010) · Journal of the American College of Cardiology

Cardiovascular Function and Risk FactorsCardiac Imaging and Diagnostics

Cited by 305

Obesity and subtypes of incident cardiovascular disease

Ndumele, C. E., Matsushita, K., Lazo, M., Bello, N., Blumenthal, R. S., Gerstenblith, G., Nambi, V., Ballantyne, C. M., Solomon, S. D., Selvin, E., et al. (2016) · Journal of the American Heart Association

Cardiovascular Function and Risk FactorsDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 259

Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF

Curtain, J. P., Docherty, K. F., Jhund, P. S., Petrie, M. C., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., et al. (2021) · European Heart Journal

Heart Failure Treatment and ManagementCardiac electrophysiology and arrhythmias

Cited by 256

Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document

Zannad, F., Garcia, A. A., Anker, S. D., Armstrong, P. W., Calvo, G., Cleland, J. G. F., Cohn, J. N., Dickstein, K., Domanski, M. J., Ekman, I., et al. (2013) · European Journal of Heart Failure

Heart Failure Treatment and ManagementStatistical Methods in Clinical Trials

Cited by 231

Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved

Rogers, J. K., Pocock, S. J., McMurray, J. J. V., Granger, C. B., Michelson, E. L., Östergren, J., Pfeffer, M. A., Solomon, S. D., Swedberg, K., & Yusuf, S. (2014) · European Journal of Heart Failure

Heart Failure Treatment and ManagementStatistical Methods in Clinical Trials

Cited by 226

The Dapagliflozin And Prevention of Adverse-Outcomes in Heart Failure (DAPA-HF) Trial: Baseline Characteristics

McMurray, J. J. V., DeMets, D. L., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Langkilde, A. M., Martinez, F. A., Bengtsson, O., Ponikowski, P., Sabatine, M. S., et al. (2019) · European Journal of Heart Failure

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 222

Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF

Martinez, F. A., Serenelli, M., Nicolau, J. C., Petrie, M. C., Chiang, C.-E., Tereshchenko, S., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., et al. (2020) · Circulation

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 210

Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting: Evidence From the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF)

Okumura, N., Jhund, P. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Swedberg, K., Zile, M. R., Solomon, S. D., et al. (2016) · Circulation

Heart Failure Treatment and ManagementHeart rate and cardiovascular health

Cited by 186